NCT00316173 - Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

March 31, 2009

Conditions

Ovarian CancerNeoplasms, Ovarian

Interventions

DRUG

topotecan

HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1

DRUG

CARBOPLATIN

HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1

Trial Locations (22)

11718

GSK Investigational Site, Brightwaters

12208

GSK Investigational Site, Albany

21404

GSK Investigational Site, Savannah

28203

GSK Investigational Site, Charlotte

29605

GSK Investigational Site, Greenville

44124

GSK Investigational Site, Mayfield Heights

46617

GSK Investigational Site, South Bend

53215

GSK Investigational Site, Milwaukee

89109

GSK Investigational Site, Las Vegas

90033

GSK Investigational Site, Los Angeles

92064

GSK Investigational Site, Poway

92868

GSK Investigational Site, Orange

94305

GSK Investigational Site, Stanford

98101

GSK Investigational Site, Seattle

06520

GSK Investigational Site, New Haven

27599-7570

GSK Investigational Site, Chapel Hill

44109-1998

GSK Investigational Site, Cleveland

84112-5550

GSK Investigational Site, Salt Lake City

T2N 4N2

GSK Investigational Site, Calgary

H2L 4M1

GSK Investigational Site, Montreal

G1R 2J6

GSK Investigational Site, Québec

J1H 5N4

GSK Investigational Site, Sherbrooke